Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 13/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660425 | 0.81 | APP (0.46) | APPCNR2CNR1 | |
| SCHEMBL1202625 | 0.80 | AKR1C3 (0.45) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15112620 | 0.80 | APP (0.50) | APPCNR2S1PR2 | |
| SCHEMBL27820430 | 0.80 | APP (0.37) | APPCNR2CNR1 | |
| SCHEMBL15112553 | 0.77 | APP (0.61) | APPS1PR2KMOPDE4APDE4B | |
| SCHEMBL15112403 | 0.75 | APP (0.56) | APPCNR2S1PR2KMOCNR1 | |
| SCHEMBL1202604 | 0.75 | AKR1C3 (0.45) | S1PR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3656867 | 0.72 | HSD11B1 (0.39) | CNR2PDE4B | |
| SCHEMBL16488437 | 0.72 | APP (0.46) | APPCNR2S1PR2KMOPDE4A | |
| SCHEMBL1202823 | 0.71 | PDE4B (0.44) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2013106328-A1 | TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8367863-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885CNR2 527/4885S1PR2 2654/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885CNR2 527/4885S1PR2 2654/4885 |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885CNR2 527/4885S1PR2 2654/4885 |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885CNR2 527/4885S1PR2 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.